Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
32
ANL Quote, Financials, Valuation and Earnings
Last price:
$8.28
Seasonality move
:
21.39%
Day range:
$7.21 - $9.20
52-week range:
$0.88 - $12.09
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.24x
Volume:
382K
Avg. volume:
1M
1-year change:
247.79%
Market cap:
$290M
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ANL
Adlai Nortye Ltd.
|
-- | -$1.31 | -- | -33.06% | $31.00 |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
VBIZF
Viva Biotech Holdings
|
-- | -- | -- | -- | -- |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$122.7M | -$0.42 | 10.78% | -4.05% | $41.44 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ANL
Adlai Nortye Ltd.
|
$7.86 | $31.00 | $290M | -- | $0.00 | 0% | -- |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
VBIZF
Viva Biotech Holdings
|
$0.3434 | -- | $724.5M | 19.39x | $0.00 | 0% | 3.15x |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
$10.21 | -- | $20.7B | 29.93x | $0.00 | 0% | 7.71x |
|
ZLAB
Zai Lab Ltd.
|
$19.22 | $41.44 | $2.2B | -- | $0.00 | 0% | 4.56x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ANL
Adlai Nortye Ltd.
|
-- | 1.287 | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.076 | 12.91% | 11.22x |
|
VBIZF
Viva Biotech Holdings
|
24.82% | -7.332 | -- | 1.26x |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
5.93% | 0.176 | -- | 1.98x |
|
ZLAB
Zai Lab Ltd.
|
23.86% | 0.191 | 11.48% | 2.18x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ANL
Adlai Nortye Ltd.
|
-- | -- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
VBIZF
Viva Biotech Holdings
|
-- | -- | -1.17% | -1.8% | -- | -- |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
-- | -- | 7.16% | 7.53% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$65.6M | -$69.7M | -17.96% | -22.45% | -54.4% | -$19.1M |
Adlai Nortye Ltd. vs. Competitors
-
Which has Higher Returns ANL or SVA?
Sinovac Biotech Ltd. has a net margin of -- compared to Adlai Nortye Ltd.'s net margin of --. Adlai Nortye Ltd.'s return on equity of -- beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital ANLAdlai Nortye Ltd.-- -- -- SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About ANL or SVA?
Adlai Nortye Ltd. has a consensus price target of $31.00, signalling upside risk potential of 294.4%. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Adlai Nortye Ltd. has higher upside potential than Sinovac Biotech Ltd., analysts believe Adlai Nortye Ltd. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ANLAdlai Nortye Ltd.2 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is ANL or SVA More Risky?
Adlai Nortye Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.790, suggesting its less volatile than the S&P 500 by 21.049%.
-
Which is a Better Dividend Stock ANL or SVA?
Adlai Nortye Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Adlai Nortye Ltd. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios ANL or SVA?
Adlai Nortye Ltd. quarterly revenues are --, which are smaller than Sinovac Biotech Ltd. quarterly revenues of --. Adlai Nortye Ltd.'s net income of -- is lower than Sinovac Biotech Ltd.'s net income of --. Notably, Adlai Nortye Ltd.'s price-to-earnings ratio is -- while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adlai Nortye Ltd. is -- versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANLAdlai Nortye Ltd.-- -- -- -- SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns ANL or VBIZF?
Viva Biotech Holdings has a net margin of -- compared to Adlai Nortye Ltd.'s net margin of --. Adlai Nortye Ltd.'s return on equity of -- beat Viva Biotech Holdings's return on equity of -1.8%.
Company Gross Margin Earnings Per Share Invested Capital ANLAdlai Nortye Ltd.-- -- -- VBIZFViva Biotech Holdings-- -- $694.7M -
What do Analysts Say About ANL or VBIZF?
Adlai Nortye Ltd. has a consensus price target of $31.00, signalling upside risk potential of 294.4%. On the other hand Viva Biotech Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Adlai Nortye Ltd. has higher upside potential than Viva Biotech Holdings, analysts believe Adlai Nortye Ltd. is more attractive than Viva Biotech Holdings.
Company Buy Ratings Hold Ratings Sell Ratings ANLAdlai Nortye Ltd.2 0 0 VBIZFViva Biotech Holdings0 0 0 -
Is ANL or VBIZF More Risky?
Adlai Nortye Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viva Biotech Holdings has a beta of 0.576, suggesting its less volatile than the S&P 500 by 42.44%.
-
Which is a Better Dividend Stock ANL or VBIZF?
Adlai Nortye Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viva Biotech Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adlai Nortye Ltd. pays -- of its earnings as a dividend. Viva Biotech Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANL or VBIZF?
Adlai Nortye Ltd. quarterly revenues are --, which are smaller than Viva Biotech Holdings quarterly revenues of --. Adlai Nortye Ltd.'s net income of -- is lower than Viva Biotech Holdings's net income of --. Notably, Adlai Nortye Ltd.'s price-to-earnings ratio is -- while Viva Biotech Holdings's PE ratio is 19.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adlai Nortye Ltd. is -- versus 3.15x for Viva Biotech Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANLAdlai Nortye Ltd.-- -- -- -- VBIZFViva Biotech Holdings3.15x 19.39x -- --
-
Which has Higher Returns ANL or WXXWY?
WuXi Biologics (Cayman), Inc. has a net margin of -- compared to Adlai Nortye Ltd.'s net margin of --. Adlai Nortye Ltd.'s return on equity of -- beat WuXi Biologics (Cayman), Inc.'s return on equity of 7.53%.
Company Gross Margin Earnings Per Share Invested Capital ANLAdlai Nortye Ltd.-- -- -- WXXWYWuXi Biologics (Cayman), Inc.-- -- $6.6B -
What do Analysts Say About ANL or WXXWY?
Adlai Nortye Ltd. has a consensus price target of $31.00, signalling upside risk potential of 294.4%. On the other hand WuXi Biologics (Cayman), Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Adlai Nortye Ltd. has higher upside potential than WuXi Biologics (Cayman), Inc., analysts believe Adlai Nortye Ltd. is more attractive than WuXi Biologics (Cayman), Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANLAdlai Nortye Ltd.2 0 0 WXXWYWuXi Biologics (Cayman), Inc.0 0 0 -
Is ANL or WXXWY More Risky?
Adlai Nortye Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison WuXi Biologics (Cayman), Inc. has a beta of -0.063, suggesting its less volatile than the S&P 500 by 106.255%.
-
Which is a Better Dividend Stock ANL or WXXWY?
Adlai Nortye Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. WuXi Biologics (Cayman), Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adlai Nortye Ltd. pays -- of its earnings as a dividend. WuXi Biologics (Cayman), Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANL or WXXWY?
Adlai Nortye Ltd. quarterly revenues are --, which are smaller than WuXi Biologics (Cayman), Inc. quarterly revenues of --. Adlai Nortye Ltd.'s net income of -- is lower than WuXi Biologics (Cayman), Inc.'s net income of --. Notably, Adlai Nortye Ltd.'s price-to-earnings ratio is -- while WuXi Biologics (Cayman), Inc.'s PE ratio is 29.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adlai Nortye Ltd. is -- versus 7.71x for WuXi Biologics (Cayman), Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANLAdlai Nortye Ltd.-- -- -- -- WXXWYWuXi Biologics (Cayman), Inc.7.71x 29.93x -- --
-
Which has Higher Returns ANL or ZLAB?
Zai Lab Ltd. has a net margin of -- compared to Adlai Nortye Ltd.'s net margin of -39.51%. Adlai Nortye Ltd.'s return on equity of -- beat Zai Lab Ltd.'s return on equity of -22.45%.
Company Gross Margin Earnings Per Share Invested Capital ANLAdlai Nortye Ltd.-- -- -- ZLABZai Lab Ltd.51.15% -$0.46 $939.8M -
What do Analysts Say About ANL or ZLAB?
Adlai Nortye Ltd. has a consensus price target of $31.00, signalling upside risk potential of 294.4%. On the other hand Zai Lab Ltd. has an analysts' consensus of $41.44 which suggests that it could grow by 115.63%. Given that Adlai Nortye Ltd. has higher upside potential than Zai Lab Ltd., analysts believe Adlai Nortye Ltd. is more attractive than Zai Lab Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ANLAdlai Nortye Ltd.2 0 0 ZLABZai Lab Ltd.8 1 0 -
Is ANL or ZLAB More Risky?
Adlai Nortye Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.854, suggesting its less volatile than the S&P 500 by 14.611%.
-
Which is a Better Dividend Stock ANL or ZLAB?
Adlai Nortye Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adlai Nortye Ltd. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANL or ZLAB?
Adlai Nortye Ltd. quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $128.2M. Adlai Nortye Ltd.'s net income of -- is lower than Zai Lab Ltd.'s net income of -$50.6M. Notably, Adlai Nortye Ltd.'s price-to-earnings ratio is -- while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adlai Nortye Ltd. is -- versus 4.56x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANLAdlai Nortye Ltd.-- -- -- -- ZLABZai Lab Ltd.4.56x -- $128.2M -$50.6M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Mar 2
Applied Optoelectronics, Inc. [AAOI] is up 21.71% over the past day.
Buy
90
BNAI alert for Mar 2
Brand Engagement Network, Inc. [BNAI] is up 2.44% over the past day.
Sell
36
WLDN alert for Mar 2
Willdan Group, Inc. [WLDN] is down 1.93% over the past day.
